

Jean-Luc Reny

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5998212/publications.pdf>

Version: 2024-02-01

123
papers

5,055
citations

117625

34
h-index

95266

68
g-index

130
all docs

130
docs citations

130
times ranked

6137
citing authors

#	ARTICLE	IF	CITATIONS
1	Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 113-116.	1.1	6
2	Confidence and use of physical examination and point-of-care ultrasonography for detection of abdominal or pleural free fluid. A cross-sectional survey. <i>Internal and Emergency Medicine</i> , 2022, 17, 113-122.	2.0	1
3	Eight versus 28-point lung ultrasonography in moderate acute heart failure: a prospective comparative study. <i>Internal and Emergency Medicine</i> , 2022, 17, 1375-1383.	2.0	6
4	Outcomes with revascularization and medical therapy in patients with coronary disease and chronic kidney disease: A meta-analysis. <i>Atherosclerosis</i> , 2022, 351, 41-48.	0.8	7
5	One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals. <i>Journal of Internal Medicine</i> , 2022, 292, 103-115.	6.0	26
6	Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting. <i>Journal of Personalized Medicine</i> , 2022, 12, 526.	2.5	12
7	Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and Glycoprotein Activities. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1268-1277.	4.7	22
8	Role of Clinical Characteristics and Biomarkers at Admission to Predict One-Year Mortality in Elderly Patients with Pneumonia. <i>Journal of Clinical Medicine</i> , 2022, 11, 105.	2.4	6
9	Accuracy of a score predicting the presence of an atypical pathogen in hospitalized patients with moderately severe community-acquired pneumonia. <i>BMC Infectious Diseases</i> , 2022, 22, 424.	2.9	2
10	PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. <i>BMJ</i> , The, 2022, 377, e069066.	6.0	30
11	Kinetics of inflammatory biomarkers to predict one-year mortality in older patients hospitalized for pneumonia: a multivariable analysis. <i>International Journal of Infectious Diseases</i> , 2022, 122, 63-69.	3.3	0
12	Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 353-363.	4.7	5
13	Risk stratification for hospital-acquired venous thromboembolism in medical patients (RISE): Protocol for a prospective cohort study. <i>PLoS ONE</i> , 2022, 17, e0268833.	2.5	6
14	Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial. <i>Clinical and Translational Science</i> , 2022, 15, 1796-1804.	3.1	6
15	Mixing Drugs and Genetics: A Complex Hemorrhagic Cocktail. <i>American Journal of Medicine</i> , 2021, 134, e211-e212.	1.5	3
16	Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 225-245.	9.4	74
17	Methods to Investigate miRNA Function: Focus on Platelet Reactivity. <i>Thrombosis and Haemostasis</i> , 2021, 121, 409-421.	3.4	18
18	Role of Intermediate Care Unit Admission and Noninvasive Respiratory Support during the COVID-19 Pandemic: A Retrospective Cohort Study. <i>Respiration</i> , 2021, 100, 786-793.	2.6	17

#	ARTICLE	IF	CITATIONS
19	Head-to-Head Evaluation of Five Automated SARS-CoV-2 Serology Immunoassays in Various Prevalence Settings. <i>Journal of Clinical Medicine</i> , 2021, 10, 1605.	2.4	5
20	An Ex Vivo and In Silico Study Providing Insights into the Interplay of Circulating miRNAs Level, Platelet Reactivity and Thrombin Generation: Looking beyond Traditional Pharmacogenetics. <i>Journal of Personalized Medicine</i> , 2021, 11, 323.	2.5	5
21	miR-204-5p and Platelet Function Regulation: Insight into a Mechanism Mediated by CDC42 and GPIIb/IIIa. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1206-1219.	3.4	6
22	Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians. <i>American Journal of Medicine</i> , 2021, 134, 939-942.	1.5	13
23	Prognosis of Laboratory-Confirmed Influenza and Respiratory Syncytial Virus in Acute Heart Failure. <i>Journal of Clinical Medicine</i> , 2021, 10, 4546.	2.4	1
24	Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1358-1367.	4.7	36
25	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 203-210.	3.0	69
26	Accuracy of C-reactive protein, procalcitonin, serum amyloid A and neopterin for low-dose CT-scan confirmed pneumonia in elderly patients: A prospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0239606.	2.5	13
27	Diagnostic accuracy of Augurix COVID-19 IgG serology rapid test. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13357.	3.4	31
28	Head-to-Head Accuracy Comparison of Three Commercial COVID-19 IgM/IgG Serology Rapid Tests. <i>Journal of Clinical Medicine</i> , 2020, 9, 2369.	2.4	30
29	Guillain-Barré syndrome as a complication of SARS-CoV-2 infection. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 111-112.	4.1	96
30	Vegetarian, pescatarian and flexitarian diets: sociodemographic determinants and association with cardiovascular risk factors in a Swiss urban population. <i>British Journal of Nutrition</i> , 2020, 124, 844-852.	2.3	42
31	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1067-1077.	4.7	32
32	MicroRNA-126 is a regulator of platelet-supported thrombin generation. <i>Platelets</i> , 2020, 31, 746-755.	2.3	17
33	Feasibility and safety of high-intensity interval training for the rehabilitation of geriatric inpatients (HIITERGY) a pilot randomized study. <i>BMC Geriatrics</i> , 2020, 20, 197.	2.7	13
34	Contribution of exome sequencing to the identification of genes involved in the response to clopidogrel in cardiovascular patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1425-1434.	3.8	2
35	Point of care ultrasonography from the emergency department to the internal medicine ward: current trends and perspectives. <i>Internal and Emergency Medicine</i> , 2020, 15, 395-408.	2.0	27
36	Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s. <i>Journal of Clinical Medicine</i> , 2020, 9, 194.	2.4	12

#	ARTICLE	IF	CITATIONS
37	Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs. <i>Swiss Medical Weekly</i> , 2020, 150, w20446.	1.6	21
38	The well-being of Swiss general internal medicine residents. <i>Swiss Medical Weekly</i> , 2020, 150, w20255.	1.6	8
39	Title is missing!. , 2020, 15, e0239606.		0
40	Title is missing!. , 2020, 15, e0239606.		0
41	Title is missing!. , 2020, 15, e0239606.		0
42	Title is missing!. , 2020, 15, e0239606.		0
43	Associations between early handoffs, length of stay and complications in internal medicine wards: A retrospective study. <i>European Journal of Internal Medicine</i> , 2019, 67, 77-83.	2.2	5
44	Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1517-1532.	3.5	6
45	Platelet Function Testing or Genotyping. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1867-1868.	2.9	1
46	Functional Validation of microRNA-126-3p as a Platelet Reactivity Regulator Using Human Haematopoietic Stem Cells. <i>Thrombosis and Haemostasis</i> , 2019, 119, 254-263.	3.4	32
47	Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0213940.	2.5	49
48	A high glucose level is associated with decreased aspirin-mediated acetylation of platelet cyclooxygenase (COX)-1 at serine 529: A pilot study. <i>Journal of Proteomics</i> , 2019, 192, 258-266.	2.4	9
49	Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1267-1293.	3.5	36
50	Low-dose computed tomography for the diagnosis of pneumonia in elderly patients: a prospective, interventional cohort study. <i>European Respiratory Journal</i> , 2018, 51, 1702375.	6.7	56
51	Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1347-1354.	3.5	52
52	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points- Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). <i>American Heart Journal</i> , 2018, 198, 152-159.	2.7	24
53	Functional Performances on Admission Predict In-Hospital Falls, Injurious Falls, and Fractures in Older Patients: A Prospective Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 852-859.	2.8	24
54	Large bowel obstruction: a case of uncommon aetiology of a frequent condition. <i>Age and Ageing</i> , 2018, 47, 487-487.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Type I Gaucher disease with bullous pemphigoid and Parkinson disease. <i>Medicine (United States)</i> , 2018, 97, e0188.	1.0	2
56	Platelet reactivity in stable cardiovascular patients with chronic kidney disease. <i>Platelets</i> , 2018, 29, 455-462.	2.3	8
57	Diagnosis of systemic lupus erythematosus by presence of Hargraves cells in eosinophilic pleural effusion. <i>Medicine (United States)</i> , 2018, 97, e12871.	1.0	2
58	Shotgun proteomics data on the impact of hyperglycaemia on platelet protein acetylation by aspirin. <i>Data in Brief</i> , 2018, 21, 2475-2481.	1.0	2
59	Pannexin1 Single Nucleotide Polymorphism and Platelet Reactivity in a Cohort of Cardiovascular Patients. <i>Cell Communication and Adhesion</i> , 2017, 23, 11-15.	1.0	10
60	Why Has Model-Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 646-656.	4.7	169
61	Antiplatelet therapy: indications and limitations in the elderly population. <i>Sang Thrombose Vaisseaux</i> , 2017, 29, 163-167.	0.1	0
62	Antiplatelet therapy: indications and limitations in the elderly population. <i>Hematologie</i> , 2016, 22, 315-318.	0.0	0
63	Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. <i>Thrombosis and Haemostasis</i> , 2016, 115, 823-825.	3.4	32
64	Acute Appendicitis in Elderly Adults: A Difficult Diagnosis. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1377-1379.	2.6	1
65	Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 295-304.	4.7	36
66	<i>TRAF3</i> Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke. <i>Stroke</i> , 2016, 47, 1180-1186.	2.0	46
67	New molecular insights into modulation of platelet reactivity in aspirin-treated patients using a network-based approach. <i>Human Genetics</i> , 2016, 135, 403-414.	3.8	21
68	<i>PPM1A</i> Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients. <i>Stroke</i> , 2016, 47, 1926-1929.	2.0	28
69	Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. <i>Platelets</i> , 2016, 27, 196-202.	2.3	10
70	Pharmacogenomics of Oral Antithrombotic Drugs. <i>Current Pharmaceutical Design</i> , 2016, 22, 1933-1949.	1.9	13
71	A Case of Tuberculous Granulomatous Panniculitis without Vasculitis. <i>Case Reports in Dermatology</i> , 2015, 7, 141-145.	0.8	3
72	Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 449-452.	1.8	8

#	ARTICLE	IF	CITATIONS
73	Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty-Five Years or Older: Results of a Multicenter, Open-Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide-Based Induction Therapy. <i>Arthritis and Rheumatology</i> , 2015, 67, 1117-1127.	5.6	150
74	Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: Anex vivostudy. <i>Platelets</i> , 2015, 26, 324-330.	2.3	33
75	Suspicion of heparin-induced thrombocytopenia in internal medicine: How appropriate is the ordering of anti-PF4/heparin antibody testing?. <i>Platelets</i> , 2015, 26, 632-637.	2.3	8
76	An Unusual Cause of Bilateral Lower Extremity Edema in an Older Woman. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 615-616.	2.6	0
77	Prothrombin G20210A Mutation and Lower Extremity Peripheral Arterial Disease: A Systematic Review and Meta-analysis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2015, 50, 232-240.	1.5	15
78	Antiplatelet Therapy: Targeting the TxA2 Pathway. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 29-38.	2.4	72
79	How to manage prasugrel and ticagrelor in daily practice. <i>European Journal of Internal Medicine</i> , 2014, 25, 213-220.	2.2	11
80	Characterization of the platelet granule proteome: Evidence of the presence of MHC1 in alpha-granules. <i>Journal of Proteomics</i> , 2014, 101, 130-140.	2.4	82
81	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2261-2273.	2.8	807
82	Unraveling modulators of platelet reactivity in cardiovascular patients using omics strategies: Towards a network biology paradigm. <i>Translational Proteomics</i> , 2013, 1, 25-37.	1.2	5
83	Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping. <i>Journal of the American Heart Association</i> , 2013, 2, e000131.	3.7	20
84	Severe Mitral Valve Regurgitation in Polymyositis. <i>Journal of Clinical Rheumatology</i> , 2012, 18, 367-369.	0.9	4
85	Prevalence of poor biological response to clopidogrel. <i>Thrombosis and Haemostasis</i> , 2012, 107, 494-506.	3.4	81
86	Intramural Hematoma of the Esophagus. <i>Case Reports in Gastroenterology</i> , 2012, 6, 510-517.	0.6	18
87	Poor Responsiveness to Antiplatelet Drugs in Acute Coronary Syndromes: Clinical Relevance and Management. <i>Cardiovascular Therapeutics</i> , 2012, 30, e41-50.	2.5	6
88	The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel <i>in vitro</i> . <i>British Journal of Pharmacology</i> , 2012, 166, 2362-2370.	5.4	18
89	Antiplatelet Drug Response Status Does Not Predict Recurrent Ischemic Events in Stable Cardiovascular Patients. <i>Circulation</i> , 2012, 125, 3201-3210.	1.6	82
90	Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1242-1251.	3.8	62

#	ARTICLE	IF	CITATIONS
91	Platelet proteomics. <i>Mass Spectrometry Reviews</i> , 2012, 31, 331-351.	5.4	43
92	Platelet reactivity is a stable and global phenomenon in aspirin-treated cardiovascular patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 466-474.	3.4	11
93	Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1664-1666.	3.8	48
94	Paternal endothelial protein C receptor 219Gly variant as a mild and limited risk factor for deep vein thrombosis during pregnancy. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 707-713.	3.8	11
95	Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 923-933.	3.8	113
96	Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2614-2623.	3.8	71
97	Admission NT-proBNP levels, renal insufficiency and age as predictors of mortality in elderly patients hospitalized for acute dyspnea. <i>European Journal of Internal Medicine</i> , 2009, 20, 14-19.	2.2	14
98	Acute Coronary Syndrome and its Antithrombotic Treatment: Focus on Aspirin and Clopidogrel Resistance. <i>Current Vascular Pharmacology</i> , 2009, 7, 198-208.	1.7	13
99	Use of the PFA-100 device closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 444-450.	3.8	130
100	Laboratory-Defined Aspirin Resistance and Recurrent Cardiovascular Events. <i>Archives of Internal Medicine</i> , 2008, 168, 549.	3.8	3
101	Aspirin response variability assessed with the PFA-100 device. <i>Thrombosis and Haemostasis</i> , 2008, 99, 968-969.	3.4	5
102	New Antiplatelet Strategies in Atherothrombosis and Their Indications. <i>European Journal of Vascular and Endovascular Surgery</i> , 2007, 34, 10-17.	1.5	28
103	A two adenine insertion polymorphism in the 3' untranslated region of factor VII gene is associated with peripheral arterial disease but not with venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2007, 98, 733-737.	3.4	4
104	A two adenine insertion polymorphism in the 3' untranslated region of factor VII gene is associated with peripheral arterial disease but not with venous thrombosis. Results of case-control studies. <i>Thrombosis and Haemostasis</i> , 2007, 98, 733-7.	3.4	0
105	Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. <i>American Heart Journal</i> , 2006, 151, 690-698.	2.7	48
106	Identification of functional polymorphisms of the thromboxane A2 receptor gene in healthy volunteers. <i>Thrombosis and Haemostasis</i> , 2006, 96, 356-360.	3.4	28
107	The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1437-1445.	3.8	67
108	P2Y1 gene polymorphism and ADP-induced platelet response. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2349-2350.	3.8	12

#	ARTICLE	IF	CITATIONS
109	The thrombomodulin-1208/-1209delTT gene promoter polymorphism does not affect basal or LPS-dependent monocyte TM mRNA transcription in healthy volunteers. <i>Thrombosis and Haemostasis</i> , 2005, 94, 686-7.	3.4	2
110	The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. <i>Thrombosis and Haemostasis</i> , 2004, 91, 248-254.	3.4	34
111	The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1334-1340.	3.8	39
112	A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. <i>Blood</i> , 2004, 103, 1311-1318.	1.4	161
113	Adenosine Diphosphate-Induced Platelet Aggregation Is Associated With P2Y ₁₂ Gene Sequence Variations in Healthy Subjects. <i>Circulation</i> , 2003, 108, 989-995.	1.6	402
114	Cleaved Protein S (PS), Total PS, Free PS, and Activated Protein C Cofactor Activity as Risk Factors for Venous Thromboembolism. <i>Clinical Chemistry</i> , 2003, 49, 575-580.	3.2	12
115	P2Y ₁₂ H2 Haplotype Is Associated With Peripheral Arterial Disease. <i>Circulation</i> , 2003, 108, 2971-2973.	1.6	156
116	An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. <i>Blood</i> , 2003, 101, 1833-1840.	1.4	99
117	Association of Takayasu's arteritis and Crohn's disease. Results of a study on 44 Takayasu patients and review of the literature. <i>Annales De Médecine Interne</i> , 2003, 154, 85-90.	0.2	32
118	Diagnosis and follow-up of infections in intensive care patients: Value of C-reactive protein compared with other clinical and biological variables*. <i>Critical Care Medicine</i> , 2002, 30, 529-535.	0.9	99
119	Combined Effect of Factor V Leiden and Prothrombin 20210A on the Risk of Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2001, 86, 809-816.	3.4	301
120	Renal and Metabolic Clearance of <i>N</i> -Acetyl-Seryl-Aspartyl-Lysyl-Proline (AcSDKP) During Angiotensin-Converting Enzyme Inhibition in Humans. <i>Hypertension</i> , 1999, 33, 879-886.	2.7	44
121	Individual Smallest Detectable Difference in Bone Mineral Density Measurements. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 1449-1456.	2.8	100
122	Tuberculosis-Related Retinal Vasculitis in an Immunocompetent Patient. <i>Clinical Infectious Diseases</i> , 1996, 22, 873-874.	5.8	13
123	Human Serum Does Not Contain a High Affinity Estrogen-Binding Glycoprotein Different from Sex Hormone-Binding Globulin*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 68, 938-945.	3.6	2